| pubmed-article:18413376 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0034603 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0178784 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0333117 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C0085101 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1522410 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1511545 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1705938 | lld:lifeskim |
| pubmed-article:18413376 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:18413376 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18413376 | pubmed:dateCreated | 2008-5-1 | lld:pubmed |
| pubmed-article:18413376 | pubmed:abstractText | Myeloablative radioimmunotherapy using (131)I-tositumomab (anti-CD20) monoclonal antibodies is an effective therapy for B-cell non-Hodgkin's lymphoma. The amount of radioactivity for radioimmunotherapy may be determined by several methods, including those based on whole-body retention and on dose to a limiting normal organ. The goal of each approach is to deliver maximal myeloablative amounts of radioactivity within the tolerance of critical normal organs. | lld:pubmed |
| pubmed-article:18413376 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18413376 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18413376 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18413376 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18413376 | pubmed:month | May | lld:pubmed |
| pubmed-article:18413376 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:GopalAjay KAK | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:RajendranJose... | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:PressOliver... | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:DurackLarry... | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:GooleyTed ATA | lld:pubmed |
| pubmed-article:18413376 | pubmed:author | pubmed-author:FisherDarrel... | lld:pubmed |
| pubmed-article:18413376 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18413376 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:18413376 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18413376 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18413376 | pubmed:pagination | 837-44 | lld:pubmed |
| pubmed-article:18413376 | pubmed:dateRevised | 2010-12-3 | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:meshHeading | pubmed-meshheading:18413376... | lld:pubmed |
| pubmed-article:18413376 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18413376 | pubmed:articleTitle | Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. | lld:pubmed |
| pubmed-article:18413376 | pubmed:affiliation | Department of Radiology, University of Washington, Seattle, Washington 98195, USA. rajan@u.washington.edu | lld:pubmed |
| pubmed-article:18413376 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18413376 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18413376 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18413376 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
